---
title: "Lysergide (DT120) in Generalized anxiety disorder: Co-prescribed/Concomitant therapies"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Co-prescribed/Concomitant therapies. Topics: Phase 3: exclusion of medications that could not be discontinued, Phase 2b: taper and washout of mood and anxiety medications, Phase 2b: medications tapered at enrollment, Phase 2b: prohibited substances, and 6 further topics. 10 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/co-prescribed-concomitant-therapies"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Co-prescribed/Concomitant therapies

<a id="heading-2.1.2.12"></a>

## 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

### Phase 3: exclusion of medications that could not be discontinued

> “Participants were excluded if they had medical or psychiatric conditions that were contraindicated, or if they were taking concomitant medications, supplements, or other therapeutics with potential drug–drug interactions or anxiolytic or antidepressant effects that could not be discontinued”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

> “Use of prohibited concomitant medications, supplements, or other therapeutics”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-2.1.2.12-2"></a>

### Phase 2b: taper and washout of mood and anxiety medications

> “The exclusion criteria included contraindicated medical or psychiatric conditions and inability or unwillingness to discontinue therapeutics with potential drug-drug interaction or anxiolytic effects.”
> “Participants taking mood or anxiety medications at screening were required to discontinue them under the supervision of site physicians.”
> “Before the baseline visit, a medication washout period of 5 half-lives or greater was required.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

> “Prior to treatment with MM120, study participants were clinically tapered and then washed out from any anxiolytic or antidepressant treatments and were not provided study-related psychotherapy for the duration of their participation in the study.”

Source: [MindMed APA presentation announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/144/mindmed-presents-phase-2b-study-of-mm120-for-generalized-anxiety-disorder-gad-at-american-psychiatric-association-apa-annual-meeting-in-new-york)

<a id="topic-2.1.2.12-3"></a>

### Phase 2b: medications tapered at enrollment

> “At screening, 84% of participants required tapering prohibited medications, 16% were treatment-naive, and 18% were receiving psychotherapy at the time of enrollment; psychotherapy was allowed to continue through the trial.”
> “Of the participants who required tapering prohibited medications, 43% were taking serotonin reuptake inhibitors, 34% were taking benzodiazepines, and 19% were taking antipsychotics or antiepileptics.”
> “Participants may have tapered multiple medications.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-2.1.2.12-4"></a>

### Phase 2b: prohibited substances

> “Disclosure or detection of the use of prohibited substances, including tetrahydrocannabinol, was cause for screening failure or discontinuation as was the use of any psychedelic within the past 2 years or more than 10 times within the past 10 years.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-2.1.2.12-5"></a>

### Monotherapy design and unstudied concomitant use

> “Sixth, the process of tapering participants from prohibited psychoactive medications ensured MM120 was assessed as a monotherapy; however, we did not address concomitant use of other pharmacotherapies.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-2.1.2.12-6"></a>

### Psychotherapy: phase 2b rules

> “Participants undergoing psychotherapy at the time of screening could enroll but could not discontinue or modify session frequency during the study.”
> “Participants not receiving psychotherapy at screening could not initiate it during the trial.”
> “Engaging in psychotherapy with the participant was explicitly prohibited by the trial protocol (Supplement 1).”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-2.1.2.12-7"></a>

### Psychotherapy: Phase 3 rules

> “Systematic psychotherapy ≤4 weeks prior to screening or plans to initiate therapy”
> “Psychotherapy was prohibited during dosing sessions.”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-2.1.2.12-8"></a>

### Psychotherapy: sponsor treatment paradigm

> “DT120 ODT Treatment Paradigm: Standalone Drug Effects with No Psychotherapeutic Intervention”
> “No psychotherapy and no therapeutic intervention beyond study drug”
> “Follow-up visits for assessment only”

Source: [Definium Therapeutics Investor and Analyst Day presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23529/pdf/DFTX+Investor+%26+Analyst+Day+Deck_April+22+2026.pdf)

> “Psychotherapy is not offered or required but may be added outside a dosing session based on a decision between a provider and patient to support individual goals and needs.”

Source: [MindMed corporate presentation (2025)](https://definiumtx.com/wp-content/uploads/2025/11/MindMed-Corporate-Presentation_November-2025.pdf)

<a id="topic-2.1.2.12-9"></a>

### Concomitant selective serotonin reuptake inhibitor: healthy-participant interaction study

> “The present findings suggest that add‐on treatment with LSD to an SSRI is well‐tolerated.”
> “No signs of serotonergic toxicity occurred in either study.”
> “SSRIs did not increase the psychedelic‐induced cardiovascular stimulation or elevation of body temperature.”

Source: [Becker et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12087691/)

> “Therefore, SSRI therapy has been discontinued before psychedelic administration in clinical Phase II trials, with the exception of one open‐label trial.”
> “However, SSRI discontinuation carries the risk of symptom relapse and withdrawal symptoms, including depressed mood.”

Source: [Becker et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12087691/)

<a id="topic-2.1.2.12-10"></a>

### Prohibited concomitant medications: regulatory guidance

> “Sponsors should evaluate potential impact of intrinsic and other extrinsic factors on the pharmacokinetics of the psychedelic drug to inform inclusion and exclusion criteria, prohibited concomitant medications for clinical studies, and potential labeling.”

Source: [FDA psychedelic drugs clinical investigations guidance (2026)](https://www.fda.gov/media/169694/download)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
